1Hermeking H. The 14-3-3 cancer connection. Nat Rev Cancer 2003; 3:931-43.
2Lodygin D, Hermeking H. The role of epigenetic silencing of 14-3-3σ in human cancer. Cell Research 2005; 15:237-46.
3Pellegrini G, Dellambra E, Golisano O, et al. P63 identifies keratinocyte stem cells. Proc Natl Acad Sci U S A 2001; 98:3156-61.
4Hermeking H, Lengauer C, Polyak K, et al. 14-3-3σ is a p53-regulated inhibitor of G2/M progression. Mol Cell 1997; 1:3-11.
5Ferguson AT, Evron E, Umbricht CB, et al. High frequency of hypermethylation at the 14-3-3σ locus leads to gene silencing in breast cancer. Proc Natl Acad Sci U S A 2000; 97:6049-54.
6Mhawech P, Benz A, Cerato C, et al. Downregulation of 14-3-3σ in ovary, prostate and endometrial carcinomas is associated with CpG island methylation. Mod Pathol 2005; 18:340-8
7Lodygin D, Diebold J, Hermeking H. Prostate cancer is characterized by epigentic silencing of 14-3-3σ expression. Oncogene 2004; 23:9034-41.
8Lodygin D, Yazdi AS, Sander CA, Herzinger T, Hermeking H.Analysis of 14-3-3σ expression in hyper-proliferative skin diseases reveals selective loss associated with CpG-methylation in basal cell carcinoma. Oncogene 2003; 22:5519-24.
9Osada H, Tatematsu Y, Yatabe Y, et al. Frequent and histological type-specific inactivation of 14-3-3σ in human lung cancers.Oncogene 2002; 21:2418-24.
10Iwata N, Yamamoto H, Sasaki S, et al. Frequent hypermethylation of CpG islands and loss of expression of the 14-3-3σ gene in human hepatocellular carcinoma. Oncogene 2000; 19: 5298-302.
